Meeting
2014 ASCO Quality Care Symposium
Adjuvant chemotherapy selection for stage I NSCLC 2011 through 2014 in the southeastern United States..
Authors
Avinash Mamgain
Oncology Analytics, Inc., Plantation, FL
Avinash Mamgain, Dinah Faith Q. Huff, Charles L. Bennett, William S. Shimp, Anmol Baranwal, Laura Rose Bobolts, Melissa Armitage, Sharon Davis, Anna E. Schorer, Marc L. Fishman, Val Fishman, Robert Walton, Jurgen Kogler, William J. Hrushesky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Science of Quality and Cost, Value, and Policy in Quality
Track
Science of Quality,Cost, Value, and Policy in Quality
Sub Track
Quality Improvement
Citation
J Clin Oncol 32, 2014 (suppl 30; abstr 248)
DOI
10.1200/jco.2014.32.30_suppl.248
Abstract #
248
Poster Bd #
E11
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
First Author: Tina Cascone
First Author: Domenico Galetta
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2024 ASCO Annual Meeting
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
First Author: Melissa Lynne Johnson